• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Alliance Fellows

2026 Alliance Fellows

The Alliance Fellows program (formerly named Global Research Ambassadors) is a virtual learning and engagement program for people impacted by ALS/MND worldwide who want to deepen their understanding of ALS/MND research, treatment development, and advocacy. Using a blended learning model that combines self-directed online content with interactive live sessions, the program helps participants build the knowledge and confidence needed to engage more meaningfully in research and advocacy conversations within the global ALS/MND community.

The program is designed to improve health literacy, strengthen global connections, and ensure that lived experience remains part of the future of ALS/MND research.

2026 Program Details

  • Delivery: Fully virtual, using Zoom and an online learning platform.
  • Duration: Four-week program delivered between September 21 and October 23 (dates tentative)
  • Structure: A blended learning approach combining self-paced learning and live interactive sessions
  • Pre-session learning: Approximately 1.5 hours of individual online learning and preparation before each live session
  • Live sessions: Nine 90-minute engaging and interactive live sessions, delivered across the four-week program. Session times will vary across time zones to support global participation and inclusivity. Sessions may be scheduled at different times throughout the day to accommodate participants from multiple regions. Recordings will also be available for those unable to attend live.
  • Learning experience: Participants will engage with expert faculty and peers through discussions, practical exercises, case studies, and collaborative activities designed to build knowledge, skills, and confidence.

How to Apply

Applications for the 2026 Alliance Fellows program are now open. The deadline to apply is Friday, July 3.

Apply Now

You are encouraged to apply if you are:

  • Living with ALS/MND
  • A current or former caregiver
  • An ALS/MND gene carrier without a diagnosis
  • A family member
  • Another member of the ALS/MND community with a strong interest in research and advocacy

Each applicant must submit a separate application.

Why the Program Matters

The program supports people affected by ALS/MND in building a stronger understanding of ALS/MND research and treatment development, clinical trials, scientific communication, research ethics, informed consent, and the important role lived experience plays in shaping research and advocacy.

Participants leave the program with:

  • A stronger understanding of ALS/MND research and treatment development
  • Greater confidence discussing scientific developments
  • Practical tools for advocacy and community engagement
  • Connections with researchers, clinicians, and peers from around the world
  • Recognition as an Alliance Fellow

Participants who complete the program receive a certificate of completion, an Alliance Fellow social media badge, recognition through Alliance communications, and opportunities to continue engaging through the Global ALS/MND Experience Network (GAMEN).

One of the program’s greatest strengths is the global community it creates — connecting people affected by ALS/MND across countries, experiences, and perspectives.

Who Should Apply?

When people affected by ALS/MND are included in research conversations, it leads to stronger advocacy, better understanding of community priorities, and more meaningful research outcomes.

You may be a strong fit for the program if you:

  • Have a personal connection to ALS/MND
  • Want to better understand ALS/MND research and treatment development
  • Are interested in advocacy or research engagement
  • Are willing to actively participate in discussions and learning activities
  • Want to connect with others in the global ALS/MND community

To participate, you will need a device with internet access and a webcam, time to attend most live sessions or watch recordings, and a willingness to learn and contribute to discussions.

If selected, participants are expected to review materials in advance, participate actively in sessions, and share what they learn with their communities following the program.

Primary Sidebar

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • David Watson, Scotland

    David Watson, Scotland

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Andrietta, Italy

    Andrietta, Italy
    Andrietta

  • Cassio Fernando da Silva, Brazil

    Cassio Fernando da Silva, Brazil

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • Willi Klein, UK

    Willi Klein, UK

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • John Sweeney, USA

    John Sweeney, USA

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • David Solomon, UK

    David Solomon, UK

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • David Bishop, UK

    David Bishop, UK

  • Mike Small, UK

    Mike Small, UK

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Wendy Hendrickson, USA

    Wendy Hendrickson, USA

  • Daniela Maria Daverio, Argentina

    Daniela Maria Daverio, Argentina

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Ali Var, Turkey

    Ali Var, Turkey

  • Jack Buzby, USA

    Jack Buzby, USA

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Dr. Shelly Hoover, USA

    Dr. Shelly Hoover, USA

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Jon Newsome, USA

    Jon Newsome, USA

  • Zabun Nassar, England

    Zabun Nassar, England

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Frank Taylor, USA

    Frank Taylor, USA

  • Mark Miller, UK

    Mark Miller, UK

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • John Dinon, Australia

    John Dinon, Australia

  • Alex, Argentina

    Alex, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login